Weill Cornell Medicine Urology
Weill Cornell Medicine Urology
Urologic Oncology (Cancer)

Urologic Oncology (Cancer)

Find a Physician

FIND A PHYSICIAN

Quickly search our world-class physicians and faculty by keyword, location and insurance provider.

Search

Recent WCM Urology Medical Publications

WCM Urology Post-Doc Named Prostate Cancer Foundation Young Investigator

Michael Augello, Ph.D. was named as a recipient of the Prostate Cancer Foundation's 2017 Young Investigator Awards. Dr. Augello is a post-doc working with Dr. Christopher Barbieri in Urology at Weill Cornell Medicine. Learn more here about prostate cancer research at Weill Cornell Medicine.

Prostate Cancer Foundation Announces 2017 Young Investigator Awards Recipients

First Clinical Trial of New Targeted Molecular Therapy in U.S. Takes Aim at Incurable Prostate Cancer

NewYork-Presbyterian and Weill Cornell Medicine clinicians in progress on Phase 1 clinical trial of PSMA-Targeted Therapeutic Agent for the Treatment for Metastatic Prostate Cancer

NewYork-Presbyterian and Weill Cornell Medicine have begun the first clinical trial in the U.S. that uses a small molecule, 177Lu-PSMA-617, to treat men with progressive prostate cancer that has spread beyond the prostate, or is metastatic, and is no longer responding to hormonal therapy.

Breaking News for Prostate Cancer

In May 2016, Dr. Jonathan Shoag with Drs. Mittal and Hu of Weill Cornell Medicine / NewYork-Presbyterian Hospital reported in the New England Journal of Medicine to demonstrate that the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial (which did not report a benefit of PSA screening) was severely flawed.

Incidence of Metastatic Prostate Cancer in Older Men Increases Following Drop in PSA Screening

The incidence of metastatic prostate cancer in older men is rising after reaching an all-time low in 2011, according to new research from Weill Cornell Medicine and NewYork-Presbyterian investigators. The findings suggest a correlation between the increase and a change in prostate cancer screening guidelines recommending against routine prostate-specific antigen (PSA) testing.

Significant decrease seen in prostate biopsy, radical prostatectomy procedures following recommendations

In a study published online by JAMA Surgery, Jim C. Hu, M.D., M.P.H., Joshua A. Halpern, M.D., M.S., of Weill Cornell Medicine, New York, and colleagues examined effects on practice patterns in prostate cancer diagnosis and treatment following the U.S. Preventative Services Task Force (USPSTF) recommendation against prostate-specific antigen (PSA) screening in 2012.

Pages

Find a Physician FIND A PHYSICIAN

© 2016 Weill Cornell Medicine All rights reserved.